Karyopharm Therapeutics Inc.
NASDAQ:KPTI · NASDAQ Global Select
+$0.50 today
Vol 0.15M · Avg 0.86M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $90.8M |
| Receivables | $23.4M |
| Inventory | $3.6M |
| Other Current | $8.5M |
| Total Current Assets | $126.3M |
| PP&E (Net) | $4.5M |
| Long-term Investments | $317.0K |
| Other Non-current | $267.0K |
| Total Non-current Assets | $5.1M |
| Total Assets | $131.4M |
Analysis
Selected assets total $131.4M for Latest. The largest visible component is Cash & Equivalents at $90.8M, about 69.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $60.5M -3.1% | $62.5M +19.6% | $52.2M -61.4% | $135.2M -29.0% | $190.5M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $3.2M -93.1% | $46.2M -66.8% | $139.2M -2.5% | $142.8M +274.2% | $38.2M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $26.2M -14.9% | $30.8M +14.1% | $27.0M -42.7% | $47.1M +109.3% | $22.5M | $533.8M | $399.4M | -$1.7B |
| Inventory | $4.0M -14.8% | $4.7M +55.7% | $3.0M -28.0% | $4.2M +2.9% | $4.1M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $9.2M -25.2% | $12.3M -1.6% | $12.5M -40.3% | $20.9M +228.9% | $6.3M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $103.1M -34.1% | $156.5M -33.1% | $233.9M -33.2% | $350.2M +27.1% | $275.6M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $4.7M -26.0% | $6.3M +28.7% | $4.9M -33.8% | $7.4M -22.8% | $9.6M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $351.0K | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $267.0K -83.7% | $1.6M +0.4% | $1.6M +158.3% | $633.0K -96.9% | $20.1M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $5.3M -33.5% | $7.9M +21.6% | $6.5M -18.6% | $8.0M -73.0% | $29.7M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $108.4M -34.1% | $164.4M -31.6% | $240.4M -32.9% | $358.2M +17.3% | $305.3M | $13.3B | $11.9B | $10.6B |
| Account Payables | $4.0M -21.6% | $5.1M +63.5% | $3.1M +12.6% | $2.8M +73.0% | $1.6M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $21.0M -14.0% | $24.4M | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $6.0M -61.7% | $15.6M -14.4% | $18.2M -15.4% | $21.5M +5.4% | $20.4M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $92.1M -0.2% | $92.3M +32.8% | $69.5M +5.4% | $65.9M -10.6% | $73.7M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $205.9M +26.4% | $162.9M -4.7% | $170.9M +0.5% | $170.1M +0.5% | $169.3M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $72.3M | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $25.3M -71.4% | $88.5M -33.7% | $133.5M +0.6% | $132.7M -0.2% | $133.0M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $309.3M +19.8% | $258.2M -16.0% | $307.2M -0.6% | $308.9M -0.8% | $311.3M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $401.3M +14.5% | $350.4M -7.0% | $376.6M +0.5% | $374.8M -2.6% | $385.0M | $14.7B | $3.7B | $9.6B |
| Common Stock | $14.0K +7.7% | $13.0K +8.3% | $12.0K +0.0% | $12.0K +50.0% | $8.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.8B -12.5% | -$1.6B -5.1% | -$1.5B -10.6% | -$1.3B -14.0% | -$1.2B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $71.0K +119.9% | -$356.0K -121.1% | -$161.0K +74.8% | -$638.0K -434.0% | $191.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | -$292.9M -57.5% | -$186.0M -36.6% | -$136.2M -717.8% | -$16.7M +79.1% | -$79.7M | $9.1B | $7.7B | $3.3B |
| Total Debt | $233.6M +20.1% | $194.5M +9.9% | $177.0M -1.1% | $179.1M -0.8% | $180.6M | $724.2M | $410.6M | $399.4M |
| Net Debt | $173.1M +31.1% | $132.0M +5.8% | $124.8M +184.3% | $43.9M +544.1% | -$9.9M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
X4 Pharmaceuticals, Inc.
NASDAQ:XFOR
$377.28M
Mersana Therapeutics, Inc.
MRSN
$145.36M
Telomir Pharmaceuticals, Inc. Common Stock
TELO
$43.32M
FibroGen, Inc.
FGEN
$36.69M
INmune Bio, Inc.
INMB
$32.97M
Aligos Therapeutics, Inc.
ALGS
$32.67M
Barinthus Biotherapeutics plc
BRNS
$27.41M
Senti Biosciences, Inc.
SNTI
$25.24M
Medicus Pharma Ltd. Common Stock
MDCX
$7.44M
CEL-SCI Corporation
CVM
$7.42M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does KPTI have?
Karyopharm Therapeutics Inc. (KPTI) reported $60.54M in cash and equivalents in fiscal 2025.
How much debt does KPTI carry?
Karyopharm Therapeutics Inc. (KPTI) reported $233.61M of total debt, with net debt of $173.07M.
Explore More
Continue the stock analysis
Jump to another research area for this company.